Kailera Therapeutics (KLRA Proposed), which is developing a weekly GLP-1 shot and a daily pill to help people lose weight, launched its $500 million IPO with an S-1/A filing early today – Monday, April 13, 2026. Kailera Therapeutics disclosed the terms – 33.33 million shares at a price range of $14.00 to $16.00 per share – in the SEC filing. At pricing, Kailera Therapeutics would have a market cap of $1.77 billion – if the IPO is priced at $15.00, the mid-point of its range.
Kailera Therapeutics aims to price its IPO on Thursday night, April 16, 2026, to trade Friday, April 17, on the NASDAQ.
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI are the joint book-running managers. William Blair is the lead manager, according to the cover of the prospectus.
The obesity-focused biotech company is based in Waltham, Massachusetts. It’s incorporated in Delaware.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.